Aspartic peptidase inhibitors: implications in drug development.

Dash C, Kulkarni A, Dunn B, Rao M. Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Mol Biol. 2003; 38(2):89-119.

View in: PubMed

subject areas

Amino Acid Sequence
Animals
Aspartic Acid Endopeptidases
Drug Design
HIV Protease Inhibitors
Humans
Molecular Sequence Data
Molecular Structure
Peptide Hydrolases
Protease Inhibitors
Renin
Sequence Homology

authors with profiles

Chandravanu Dash

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support